Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.75 |
| ▸ | HTT | P42858 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MMP13 | P45452 | 1/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7082686 | 0.92 | TSHR (0.73) | NAMPTHTTALDH1A1LMNAMAPT | |
| SCHEMBL2984197 | 0.91 | NAMPT (0.72) | NAMPTHTTALDH1A1LMNAMAPT | |
| SCHEMBL1568226 | 0.90 | ALDH1A1 (0.72) | NAMPTHTTALDH1A1LMNAMAPT | |
| SCHEMBL354041 | 0.90 | TSHR (0.76) | NAMPTUSP2GAAMAPK1KMT2A | |
| SCHEMBL16286298 | 0.90 | MEN1 (0.81) | NAMPTHTTALDH1A1LMNAMAPT | |
| Iodide SCHEMBL15903217 | 0.89 | TSHR (0.74) | NAMPTUSP2GAAMAPK1KMT2A | |
| SCHEMBL5257811 | 0.88 | LMNA (0.72) | NAMPTHTTALDH1A1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL11508166 | 0.88 | TSHR (0.72) | NAMPTUSP2GAAMAPK1KMT2A | |
| SCHEMBL6569317 | 0.88 | LMNA (0.72) | NAMPTHTTALDH1A1LMNAMAPT | |
| SCHEMBL11632041 | 0.87 | MMP13 (0.81) | NAMPTHTTALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112533904-B | Melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-108339551-B | Preparation method of novel antibacterial drug linezolid intermediate | 扬州虹光生物科技有限公司 | 2021-05-28 | — | — | CN | claimed |
| WO-2021102420-A1 | INTERFERON SIGNALING AS A CANCER BIOMARKER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | claimed |
| US-8242129-B2 | 6-phenylpyrimidinones as PIM modulators | EXELIXIS, INC. (US) | 2012-08-14 | — | — | US | claimed |
| EP-2459524-A2 | NOVEL COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTORS | Cadila Healthcare Limited (IN) | 2012-06-06 | — | — | EP | claimed |
| WO-2011016050-A2 | NOVEL COMPOUNDS AS MODULATORS OF GLUCOCORTICOID RECEPTORS | CADILA HEALTHCARE LIMITED (IN) | 2011-02-10 | — | — | WO | claimed |
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | claimed |
| EP-1928879-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | Brystol-Myers Squibb Company (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007038314-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-05 | — | — | WO | claimed |
| JP-2002537391-A | — | — | 2002-11-05 | — | — | JP | claimed |
| EP-1155012-A1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | Cancer Research Ventures Limited (GB) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050417-A1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | CANCER RESEARCH VENTURES LIMITED (GB) | 2000-08-31 | — | — | WO | claimed |
| EP-0373891-B1 | Anti-tumour agents | ICI PLC (GB) | 1994-11-02 | — | — | EP | claimed |
| EP-0373891-A2 | Anti-tumour agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-20 | — | — | EP | claimed |
| US-12391647-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-08-19 | — | — | US | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230099912-A1 | BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-03-30 | — | — | US | disclosed |
| EP-0559046-A1 | N-amidinopiperidinyl(3/4)- or N-amidino-1,4-Oxazinyl(2)-substituted sulfonamides, process for their preparation and use as thrombin inhibitors | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1993-09-08 | — | — | EP | disclosed |
| EP-0373891-A2 | Anti-tumour agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-20 | — | — | EP | disclosed |
| US-4069224-A | N-(PYRIDYLALKYL)BENZAMIDES, IMPROVE PRODUCTION OF PROSTAGLANDINS IN MAMMALS | THE UPJOHN COMPANY (US) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135954-A1 | 6-Phenylpyrimidinones as PIM Modulators | PIM1, PIM2, PIM3 | NAMPT 3139/4885HTT 2808/4885ALDH1A1 851/4885 |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | NAMPT, NAPRT, NNMT | NAMPT 1/4885HTT 1389/4885ALDH1A1 2101/4885 |
| US-12391647-B2 | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | JAK2, STAT3, STAT5A | NAMPT 478/4885HTT 2176/4885ALDH1A1 635/4885 |
| US-20230099912-A1 | BENZAMIDE COMPOUND AND PREPARATION METHOD, USE, AND PHARMACEUTICAL COMPOSITION THEREOF | JAK2, STAT3, STAT5A | NAMPT 478/4885HTT 2176/4885ALDH1A1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.